Investigational drug · Phase 3
BHV-2000
Also called: Taldefgrobep, BMS-986089
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Spinal Muscular Atrophy, Neuromuscular Diseases, SMA.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "BHV-2000"
First trial start
2022
Jul 6, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BHV-2000", any sponsor or status.
Conditions studied
As listed on its trial records.
- Spinal Muscular Atrophy
- Neuromuscular Diseases
- SMA
- Obesity
- Overweight
Approved drugs for the same conditions: Obesity and weight management · Spinal muscular atrophy · Cardiovascular and metabolic · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "BHV-2000" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular AtrophyPivotal-lookingActive, not recruiting
Biohaven Pharmaceuticals, Inc.Industry
NCT05337553 · 269 participants · Start Jul 6, 2022 · Primary completion Sep 25, 2024
Drug: taldefgrobep alfa; Placebo and 1 more · For: Spinal Muscular Atrophy; Neuromuscular Diseases; SMA
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 53 sites in all
- Taldefgrobep Alfa in Adults With Overweight and ObesityPivotal-lookingActive, not recruiting
Biohaven Therapeutics Ltd.Industry
NCT07281495 · 150 participants (planned) · Start Nov 24, 2025 · Primary completion Sep 2026
Drug: Taldefgrobep Alfa; Placebo and 2 more · For: Obesity; Overweight
Sites: Chula Vista, California; Montclair, California; Sacramento, California · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway.
Finkel RS, Crawford TO, Darras BT, et al. · Expert Rev Neurother 2026
- Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy.
Servais L, Lair LL, Connolly AM, et al. · Int J Mol Sci 2024
- The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.
Muntoni F, Byrne BJ, McMillan HJ, et al. · Neurol Ther 2024
- Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.
Rabbia M, Guridi Ormazabal M, Staunton H, et al. · J Neuromuscul Dis 2024
- LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin.
Zhu Y, D'Arienzo C, Lou Z, et al. · Bioanalysis 2016
Also in development for Spinal Muscular Atrophy
- SalanersenBIIB115Phase 33 trials
Biogen · Muscular Atrophy, Spinal, Spinal Muscular Atrophy
- NMD670Phase 23 trials
NMD Pharma A/S · Myasthenia Gravis, Myasthenia Gravis, MuSK, Charcot-Marie-Tooth Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.